[
  {
    "ts": null,
    "headline": "Moderna's Road To Stopping The Red",
    "summary": "Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my analysis of MRNA stock.",
    "url": "https://finnhub.io/api/news?id=3f32425158e4145ad62d311b81a42235e88b111cce77196f3c3bc06e7056cde9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736934773,
      "headline": "Moderna's Road To Stopping The Red",
      "id": 132400041,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1167429388/image_1167429388.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my analysis of MRNA stock.",
      "url": "https://finnhub.io/api/news?id=3f32425158e4145ad62d311b81a42235e88b111cce77196f3c3bc06e7056cde9"
    }
  }
]